Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.

Guan B, Wang H, Cao S, Rao Q, Wang Y, Zhu Y, Shi Q, Yin H, Wang X, Zhou X.

Ann Diagn Pathol. 2011 Aug;15(4):225-32. doi: 10.1016/j.anndiagpath.2010.10.006. Epub 2011 Mar 10.

PMID:
21396871
2.

May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.

Wang H, Guan B, Shi Q, Ma H, Zhou H, Wang X, Zhou X.

Med Oncol. 2011 Mar;28(1):42-50. doi: 10.1007/s12032-009-9399-1. Epub 2009 Dec 30.

PMID:
20041316
3.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
4.

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.

Cancer. 2003 Mar 15;97(6):1573-81.

PMID:
12627523
5.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

PMID:
21276138
6.

Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.

Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L.

Breast Cancer Res Treat. 2010 Dec;124(3):677-88. doi: 10.1007/s10549-010-0790-6. Epub 2010 Mar 9.

PMID:
20213083
7.

HER-2 amplification in tubular carcinoma of the breast.

Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW.

Am J Clin Pathol. 2006 Jul;126(1):55-8.

PMID:
16753605
8.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
9.
10.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
11.

Lipid-rich carcinoma of the breast. A clinicopathological study of 49 cases.

Shi P, Wang M, Zhang Q, Sun J.

Tumori. 2008 May-Jun;94(3):342-6.

PMID:
18705401
12.

Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.

Rosenthal SI, Depowski PL, Sheehan CE, Ross JS.

Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):40-6.

PMID:
11893034
13.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

PMID:
7914825
14.

A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.

Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG.

Cancer. 2003 Oct 15;98(8):1587-95.

PMID:
14534873
15.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148
16.

The association of HER-2/neu amplification with breast cancer recurrence.

Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V.

Arch Surg. 2000 Dec;135(12):1469-74.

PMID:
11115354
17.

[Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].

Liu ZB, Wu J, Ping B, Feng LQ, Shen ZZ, Shao ZM.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):610-4. Chinese.

PMID:
19102940
18.
19.

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ.

J Clin Oncol. 1997 Aug;15(8):2894-904.

PMID:
9256133
Items per page

Supplemental Content

Write to the Help Desk